Cholinergic Modulation in Alzheimer’s Disease and Cognitive Impairment

The cholinergic system, centred on the neurotransmitter acetylcholine, plays a pivotal role in learning, memory and attention. In Alzheimer’s disease (AD) and related cognitive disorders, degeneration of basal forebrain cholinergic neurons precipitates a decline in central cholinergic transmission. This deficit underlies early memory impairment and attentional disturbance, and has guided the development of symptomatic therapies such as acetylcholinesterase inhibitors and muscarinic receptor modulators. Beyond simple neurotransmitter replacement, emerging research has revealed that cholinergic pathways intersect with key pathogenic processes in AD, including amyloid-β accumulation, tau hyperphosphorylation, neuroinflammation and oxidative stress. Activation of nicotinic α7 receptors on glial cells modulates cytokine release, while M1 muscarinic agonism can influence intracellular signalling cascades linked to synaptic plasticity, notably the CREB-BDNF axis. Preclinical models employing cholinergic antagonists such as scopolamine have elucidated mechanisms of synaptic dysfunction and oxidative damage, highlighting opportunities for novel small molecules that combine enzyme inhibition with antioxidant or anti-inflammatory properties. As the global burden of dementia rises, deeper insight into cholinergic modulation offers prospects for therapies that not only relieve symptoms but also attenuate pathogenic cascades and preserve cognition.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Cholinergic Modulation in Alzheimer’s Disease and Cognitive Impairment publication trend

The graph below shows the total number of articles in cholinergic modulation in alzheimer’s disease and cognitive impairment across all publications each year (not limited to Nature Index journals).

Technical terms

Acetylcholine (ACh): A neurotransmitter essential for synaptic transmission in learning and memory circuits.

Acetylcholinesterase (AChE): The enzyme responsible for breakdown of acetylcholine at synaptic clefts.

Muscarinic receptor: A class of G-protein-coupled receptors responsive to acetylcholine, with M1 subtype linked to cognitive function.

Nicotinic receptor: A ligand-gated ion channel activated by acetylcholine, notably the α7 subtype involved in anti-inflammatory signalling.

Neuroinflammation: Activation of glial cells and release of pro-inflammatory cytokines that can impair synaptic function.

Oxidative stress: Imbalance between reactive oxygen species production and antioxidant defences, leading to cellular damage.

Brain-derived neurotrophic factor (BDNF): A neurotrophin that supports neuronal survival, differentiation and synaptic plasticity.

Nuclear factor erythroid 2-related factor 2 (Nrf2): A transcription factor that upregulates antioxidant and cytoprotective genes.

References

1. Role of Cholinergic Signaling in Alzheimer’s Disease. Molecules (2022).
2. The Cholinergic System Modulates Memory and Hippocampal Plasticity via Its Interactions with Non-Neuronal Cells. Frontiers in Immunology (2017).
3. FA‐97, a New Synthetic Caffeic Acid Phenethyl Ester Derivative, Protects against Oxidative Stress‐Mediated Neuronal Cell Apoptosis and Scopolamine‐Induced Cognitive Impairment by Activating Nrf2/HO‐1 Signaling. Oxidative Medicine and Cellular Longevity (2019).